Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake

Ilaria Manca, Andrea Mastinu, Francesca Olimpieri, Matteo Falzoi, Monica Sani, Stefania Ruiu, Giovanni Loriga, Alessandro Volonterio, Simone Tambaro, Mirko Emilio Heiner Bottazzi, Matteo Zanda, Gerard Aime Pinna, Paolo Lazzari

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1-hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl]-4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.
Original languageEnglish
Pages (from-to)256-269
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume62
Early online date11 Jan 2013
DOIs
Publication statusPublished - Apr 2013

Fingerprint

rimonabant
Eating
Derivatives
Product Recalls and Withdrawals
Pharmacology
Enantiomers
Obesity
Pharmaceutical Preparations
pyrazole

Keywords

  • cannabinoids
  • CB1 receptor
  • fluorinated ligands
  • food intake

Cite this

Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake. / Manca, Ilaria; Mastinu, Andrea; Olimpieri, Francesca; Falzoi, Matteo ; Sani, Monica; Ruiu, Stefania; Loriga, Giovanni; Volonterio, Alessandro; Tambaro, Simone; Bottazzi, Mirko Emilio Heiner; Zanda, Matteo; Pinna, Gerard Aime; Lazzari, Paolo.

In: European Journal of Medicinal Chemistry, Vol. 62, 04.2013, p. 256-269.

Research output: Contribution to journalArticle

Manca, I, Mastinu, A, Olimpieri, F, Falzoi, M, Sani, M, Ruiu, S, Loriga, G, Volonterio, A, Tambaro, S, Bottazzi, MEH, Zanda, M, Pinna, GA & Lazzari, P 2013, 'Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake', European Journal of Medicinal Chemistry, vol. 62, pp. 256-269. https://doi.org/10.1016/j.ejmech.2012.12.056
Manca, Ilaria ; Mastinu, Andrea ; Olimpieri, Francesca ; Falzoi, Matteo ; Sani, Monica ; Ruiu, Stefania ; Loriga, Giovanni ; Volonterio, Alessandro ; Tambaro, Simone ; Bottazzi, Mirko Emilio Heiner ; Zanda, Matteo ; Pinna, Gerard Aime ; Lazzari, Paolo. / Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake. In: European Journal of Medicinal Chemistry. 2013 ; Vol. 62. pp. 256-269.
@article{3b66d4d55ffa45e2b933933ed1142913,
title = "Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake",
abstract = "In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1-hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl]-4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.",
keywords = "cannabinoids, CB1 receptor, fluorinated ligands, food intake",
author = "Ilaria Manca and Andrea Mastinu and Francesca Olimpieri and Matteo Falzoi and Monica Sani and Stefania Ruiu and Giovanni Loriga and Alessandro Volonterio and Simone Tambaro and Bottazzi, {Mirko Emilio Heiner} and Matteo Zanda and Pinna, {Gerard Aime} and Paolo Lazzari",
year = "2013",
month = "4",
doi = "10.1016/j.ejmech.2012.12.056",
language = "English",
volume = "62",
pages = "256--269",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER",

}

TY - JOUR

T1 - Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake

AU - Manca, Ilaria

AU - Mastinu, Andrea

AU - Olimpieri, Francesca

AU - Falzoi, Matteo

AU - Sani, Monica

AU - Ruiu, Stefania

AU - Loriga, Giovanni

AU - Volonterio, Alessandro

AU - Tambaro, Simone

AU - Bottazzi, Mirko Emilio Heiner

AU - Zanda, Matteo

AU - Pinna, Gerard Aime

AU - Lazzari, Paolo

PY - 2013/4

Y1 - 2013/4

N2 - In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1-hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl]-4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.

AB - In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1-hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl]-4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.

KW - cannabinoids

KW - CB1 receptor

KW - fluorinated ligands

KW - food intake

U2 - 10.1016/j.ejmech.2012.12.056

DO - 10.1016/j.ejmech.2012.12.056

M3 - Article

VL - 62

SP - 256

EP - 269

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -